Goldman Sachs
SABS icon

Goldman Sachs’s SAB Biotherapeutics SABS Stock Holding History

Goldman Sachs’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$436K Buy
113,940
+62,592
+122% +$250K ﹤0.01% 5681
2025
Q4 		$192K Buy
51,348
+40,127
+358% +$132K ﹤0.01% 6052
2025
Q3 		$22.6K Buy
+11,221
New +$25.4K ﹤0.01% 6231
2022
Q4 		– Sell
-1,262
Closed -$9K – 6235
2022
Q3 		$9K Sell
1,262
-184
-13% -$1.83K ﹤0.01% 6036
2022
Q2 		$21K Sell
1,446
-103
-7% -$2.16K ﹤0.01% 6161
2022
Q1 		$58K Buy
1,549
+100
+7% +$4.62K ﹤0.01% 6239
2021
Q4 		$113K Sell
1,449
-4,051
-74% -$380K ﹤0.01% 6101
2021
Q3 		$554K Sell
5,500
-1,842
-25% -$184K ﹤0.01% 5136
2021
Q2 		$731K Hold
7,342
– – ﹤0.01% 4989
2021
Q1 		$721K Buy
+7,342
New +$734K ﹤0.01% 4855

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs's SABS Position: Q1 2026 in Review

Goldman Sachs increased its SAB Biotherapeutics (SABS) stake by 122% in Q1 2026, buying an estimated $250K and bringing the position to 113,940 shares worth $436K. The position accounts for ﹤0.01% of the portfolio, ranked #5681.

Goldman Sachs first reported a position in SABS in Q1 2021 and has held it in 10 quarters since. The position peaked at $731K in Q2 2021. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Goldman Sachs held 113,940 shares of SAB Biotherapeutics worth $436K as of Q1 2026.
  • Goldman Sachs bought 62,592 SAB Biotherapeutics shares in Q1 2026, an estimated $250K.
  • SAB Biotherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5681 holding.
  • Goldman Sachs first reported a position in SAB Biotherapeutics in Q1 2021 and has held it in 10 quarters since.
  • Goldman Sachs's SAB Biotherapeutics position peaked at $731K in Q2 2021.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.